Bengaluru, June 18 -- In a landmark achievement in cancer care, three patients treated with Chimeric Antigen Receptor T-cell (CAR T-cell) therapy for relapsed follicular lymphoma at Narayana Health City, Bengaluru, have completed three years of remission, making this one of the longest-documented survivals post-CAR T therapy in South India.
CAR T-cell therapy, an advanced form of immunotherapy, is rapidly becoming a beacon of hope for patients with relapsed or treatment-resistant lymphoma. India now manufactures CAR T-cell products domestically, with two CDSCO-approved therapies-NEXCAR19 and QARTEMI-bringing this life-saving innovation within reach of Indian patients.
One such patient, a 66-year-old homemaker, relapsed with aggressive lym...